Drugs / LV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06363825 Background | Apr 2024 → Apr 2026 overdue | hepatocellular carcinoma | Fujian Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06363825 ↗ |
| Route | Other | “LV 400mg/m\^2, arterial infusion” NCT06363825 ↗ |